Effect of ingestion of reduced coenzyme Q10 in patients with mild cognitive impairment
Not Applicable
- Conditions
- mild cognitive impairment
- Registration Number
- JPRN-UMIN000022219
- Lead Sponsor
- KAKU Neurosurgery clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1) A score of 19 or less on the Revised Hasegawa Dementia Scale (HDS-R) (2) Diagnosis of Parkinson's disease, Huntington's disease, multiple sclerosis, or epilepsy or the presence of head trauma (3) Diagnosis of schizophrenia, depression, or serious heart disorder; incomplete recovery from a malignancy; or ongoing dialysis (4) Treatment with oxidized coenzyme Q10 or reduced coenzyme Q10 within the last 2 months (5) Judgment by the investigator as being ineligible to be a study subject for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method